Abstract

Angiogenesis inhibitors in gastric cancer Timothy McCarthy,1 Bert H O'Neil2 1Division of Hematology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA; 2Indiana University School of Medicine, Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, USA Abstract: In the United States in 2013 it was estimated that 21,600 people would be diagnosed, and 10,990 would die of gastric cancer, the 14th most common type of cancer in the United States. Unfortunately, the majority of patients in Western countries present with metastatic disease, with very limited prognosis and relatively few treatment options. In recent years there has been increased interest in targeted agents in advanced gastric cancer. A common area of interest in anti-tumor therapy involves anti-angiogenic strategies. Abnormal neo-angiogenesis is a feature of many tumor types, and anti-angiogenic therapy has shown efficacy. The purpose of this article is to review the use of various angiogenesis inhibitors in gastric cancer. In addition, we will discuss in further detail ramucirumab, a new vascular endothelial growth factor receptor-2 inhibitor which has recently been approved by the US Food and Drug Administration for treatment of advanced stomach cancer or gastroesophageal junction adenocarcinoma. Keywords: gastric cancer, anti-angiogenic, ramucirumab, VEGFR2

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.